http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011033415-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_901588c5fd7e694d395d427b1975b88f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f65c61be47844d66b6755889e5107628 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_010cfd10237b8472a5de383b1128e42e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de88f1116c71f2e06b901675b74355bc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e88648dd9c0079888ede0291352d7f7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8938ab2c148b9329319366dca6add256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f853aaa9cdb9640d17fc75830ed84ba2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a50bb295dbe103d3469565284de859c1 |
| publicationDate | 2011-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2011033415-A1 |
| titleOfInvention | Agent for differentiating hematopoietic stem cell into natural killer cell comprising yc-1 or il-2 1 and a method of differentiating hematopoietic stem cell into natural killer cell using the same |
| abstract | The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity. |
| priorityDate | 2007-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 276.